Loading
Life sciences · Interventional Study
ClinicalTrials.gov · October 13, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Interventional Study.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT03901807). This is a study registration, not published results. Lead sponsor: Spectral Diagnostics (US) Inc.. Recruitment status: COMPLETED. Phase: NA. Study type: INTERVENTIONAL. Enrollment: 157 participants (ACTUAL). Conditions: Septic Shock, Endotoxemia. Interventions: DEVICE: Toraymyxin PMX 20R Extracorporeal Hemoperfusion Cartridge. Primary outcome measures: Day 28 mortality comparison , 28 days. Brief summary: Prospective, multicenter, randomized, open-label study of standard of care plus the PMX cartridge versus standard of care alone in patients with endotoxemic septic shock